HRS 7085
Alternative Names: HRS-7085Latest Information Update: 21 Dec 2023
At a glance
- Originator Atridia
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Inflammatory bowel diseases
Most Recent Events
- 19 Dec 2023 Atridia plans a phase I pharmacokinetics and pharmacodynamics trial (In volunteers) (PO, Tablet) in December 2023 (NCT06175949)
- 16 Mar 2023 Atridia completes a phase I trial in Inflammatory bowel diseases (In volunteers) in Australia (PO) (NCT05638347)
- 09 Dec 2022 Preclinical trials in Inflammatory bowel diseases in Australia (PO) (NCT05638347)